Online Inquiry

Antibody Discovery Service

Antibody discovery is a key step that directly determines the results of antibody drug development. To obtain better antibody drugs, it is necessary to expand the range of antibodies as much as possible and accurately sort out high-quality antibodies. Our company provides high-quality antibody discovery services and has a variety of antibody discovery platforms to help you make research progress in the development of rare disease antibody therapies.

Overview of Antibody Discovery

Antibody discovery is a key step in the development of antibody drugs, which can directly affect the efficacy of antibody drugs. In the process of rare disease drug development, researchers should select reasonable antibody screening technology according to the pathogenesis of the disease and the characteristics of the target, to more efficiently screen out high-quality functional antibody candidates.

2-2-4-2 Antibody Discovery Service-1Fig.1 The process of biopanning in phage display technology (Alfaleh, M. A., et al. 2020)

Antibody Discovery Technologies

The current antibody discovery methods include hybridoma technology, phage display technology, and single B cell antibody screening technology. Hybridoma technology is well-established and widely used for antibody preparation. Phage technology is also commonly used due to its high screening efficiency. Emerging technologies, such as single B cell screening, allow for direct screening of human monoclonal antibodies from humans, resulting in shorter development cycles compared to traditional methods.

Our Services

Our company provides a wide range of antibody discovery platforms, allowing customers to choose the most suitable platform based on their specific target, downstream application, desired delivery content, and timeline. This table summarizes the main advantages and drawbacks of each antibody discovery technology.

Technologies Advantages Drawbacks
Single B Cell Screen-Based Antibody Discovery
  • High antibody affinity
  • High-throughput screening
  • Best for the discovery of rare antibodies against challenging targets with maximized developability
  • Not adapted to antigens with low immunogenicity and/or toxicity
Phage Display-Based Antibody Discovery
  • No species restriction
  • Maximized diversity due to random VH-VL pairing
  • High-throughput screening allowing identification of multiple binders
  • Adapted to antigens with low immunogenicity and/or toxicity
  • No animal use thanks to premade libraries
  • Non-natural VH-VL pairing can negatively impact developability
  • Potential bias due to phage particle
  • Low/medium antibody affinity due to lack of immunizations (naïve libraries)
  • High-affinity antibodies are expensive & long to develop as they require custom immune library construction
Hybridoma Technology-Based Antibody Discovery
  • High antibody affinity
  • Preservation of natural VH-VL pairing
  • Cheap
  • High loss of diversity due to low efficiency of cell fusion
  • Limited to rodents
  • Humanization needed
  • Not adapted to antigens with low immunogenicity and/or toxicity
Humanized Transgenic Animal-Based Antibody Discovery
  • All-human monoclonal antibodies with high affinity
  • More immune-diverse
  • Better avoid the occurrence of drug resistance
  • Not adapted to antigens with low immunogenicity and/or toxicity
  • More complex production process
  • High price

Our Antibody Discovery Service Process

2-2-4-2 Antibody Discovery Service-2Antigen design
2-2-4-2 Antibody Discovery Service-3
2-2-4-2 Antibody Discovery Service-4Immunization or Immune library construction (optional)
2-2-4-2 Antibody Discovery Service-3
2-2-4-2 Antibody Discovery Service-5Cell screening or Library screening(optional)
2-2-4-2 Antibody Discovery Service-3
2-2-4-2 Antibody Discovery Service-6Isolation and selection of the best antibody

Please note that this process provides a general overview and each technology may vary. You can contact our experts with specific project requirements to determine the most suitable antibody discovery technology. Alternatively, you can refer to our Therapeutic Antibody Development Platforms for more rare disease antibody therapy information.


  • Alfaleh, M. A., et al. "Phage display derived monoclonal antibodies: from bench to bedside. Front Immunol 11: 1986." (2020).

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services

Copyright © Protheragen. All rights reserves.